Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breath-Tracking sensor aims to sharpen lung cancer scans

NCT ID NCT01720186

Diagnosis Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing a breathing sensor called SPI that synchronizes PET/CT scans with a patient's breath. The goal is to see if this device can produce clearer images of lung tumors and nodules. Each participant undergoes a scan with both the SPI device and a standard breathing monitor, so the two methods can be compared directly. The study focuses on whether patients can tolerate the device and whether it accurately detects breathing cycles to improve image quality.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a breathing sensor (pneumotachograph) that synchronizes PET/CT scans with the patient's breath
What this could lead to
If it works, this device could help doctors get clearer, more accurate PET/CT images of lung tumors by timing scans to the patient's breathing.
What could go wrong
This is a small pilot study with 46 patients at one center. The device may not track breathing reliably for everyone, and the approach might not improve image quality enough to replace standard methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

46 people

The number who actually took part.

Start date

May 2013

Finished

Sep 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient for whom there is an indication of PET/CT 18FDG imaging for thoracic oncology ; this indication is consistent with the Standard Options Recommendations or was validated during Multidisciplinary Consultation Meeting : * Either an extension assessment of non-small cell lung cancer; * Either the characterization of single pulmonary nodule; Or - the definition of the target volume in radiotherapy. 2. Patient who meets the following criteria to be eligible for an PET/CT imaging: * Patient able to maintain a supine position for 60 minutes * Patient with no bronchopulmonary infection and with no upper aero digestive tract acute infection in progress (increased risk of false positives) 3. Age ≥ 18 years 4. WHO ≤ 1 5. Well-informed written consent signed by the patient and collected before any specific procedure in the study 6. Patient member in a national insurance scheme Exclusion Criteria: 1. Patient with a bronchial carcinoid or bronchoalveolar cancer 2. Patient with acute bronchopneumopathy 3. Not stabilized diabetic patient 4. Patient with an absolute indication against spirometry: ongoing pneumothorax or within the previous month, pleural biopsy or puncture within the previous month, hemoptysis, severe asthma, tuberculosis 5. Any usual relative indication against spirometry: ongoing bronchial infections, acute asthma, decompensation of chronic respiratory failure, respiratory pain 6. Any usual formal indication against imaging examination PET/CT (important claustrophobia) 7. Patient unable to follow study procedures 8. Pregnant women or nursing mothers can not participate in the study 9. Men and women of childbearing age must use effective contraception at study entry and throughout the study 10. Any other medical conditions making the inclusion of the patient in the study inappropriate in the opinion of the investigator 11. Patient under legal guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung nodule are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma pulmonary coin lesion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung nodule Non-small cell lung cancer

Contacts and locations

Locations

  • Institut Claudius REGAUD

    Toulouse, 31052, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.